雷公藤多苷治疗结缔组织病相关间质性肺病的临床效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Tripterygium Glycosides in the treatment of connective tissue disease related interstitial lung disease (CTD-ILD). Methods A total of 40 patients with CTD-ILD admitted to our hospital from April to October 2019 were selected and randomly divided into the control group and the experiment group, with 20 cases in each group. The control group was treated with Glucocorticoids, and the experiment group was given Tripterygium Glycosides treatment on the basis of the control group. The clinical treatment efficiency, improvement of lung function, incidence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experiment group was 80.00%, which was higher than 65.00% in the control group, the difference was statistically significant (P＜0.05). Before treatment, there were no significant difference in the levels of total lung volume (TLC), CO diffusion (DLCO), and arterial oxygen partial pressure (PaO2) between the two groups (P＞0.05). After treatment, the levels of TLC, DLCO, and PaO2 were higher than those before treatment in the two groups,and the levels of TLC, DLCO, and PaO2 in the experiment group were higher than those in the control group (P＜0.05).The total incidence of drug side effect in the experiment group was lower than that in the control group (P＜0.05). Conclusion Tripterygium Glycosides has a significant clinical effect on CTD-ILD, which can significantly improve the patient′s lung function, and has low incidence of adverse reactions. It may become one of the options in the treatment of CTD-ILD.

Key words： Tripterygium Glycosides Lung function Clinical efficacy

Received: 08 June 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/32

[1]	Fischer A，Distler J.Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases[J].Clin Rheumatol，2019，38（10）：2673-2681.
[2]	黄莎，杨朝，郭东更.结缔组织病相关间质性肺病治疗的研究进展[J].国际呼吸杂志，2018，38（10）：758-762.
[3]	杜毅鹏，葛欣宜，周晨，等.支气管肺泡灌洗在自身免疫特征的间质性肺炎与结缔组织病相关间质性肺疾病中的应用[J].中国微创外科杂志，2018，18（3）：220-224.
[4]	章敏，高润娣，王真.中医药治疗结缔组织病相关间质性肺病进展[J].浙江中医杂志，2019，12（11）：154-156.
[5]	Adelle SJ，Stephen A，Jane B，et al.Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD（CTD-ILD） and Interstitial Pneumonia with Autoimmune Features （IPAF）[J].J Clin Med，2017，6（5）：51.
[6]	王迁，李梦涛，曾小峰.结缔组织病相关间质性肺病：多科协作，规范诊治，探索更合理的治疗策略[J].中华内科杂志，2018，57（8）：552-553.
[7]	欧佳莉.结缔组织病相关间质性肺疾病的胸部HRCT 及肺功能特征分析[D].银川：宁夏医科大学，2019.
[8]	赵娜，陈立辉，张玉柱，等.结缔组织病相关间质性肺疾病的治疗研究进展[J].世界临床药物，2018，39（6）：427-430.
[9]	程利，严丽娟.糖皮质激素联合静脉丙种球蛋白治疗结缔组织病相关间质性肺疾病的疗效观察[J].中国医药科学，2019，9（20）：77-79.
[10]	王妍华，蒲丹，罗静，等.147 例常见结缔组织病相关间质性肺病的临床特征及转归分析[J].西安交通大学学报（医学版），2019，40（4）：598-603.
[11]	王君丽，于宝丹，徐军，等.结缔组织病相关性间质性肺疾病患者外周血Th1/Th2 细胞的表达[J].临床肺科杂志，2016，21（5）：828-830.
[12]	杨锡光，陈卫松，徐继林，等.结缔组织疾病相关性间质性肺疾病186 例临床特点分析[J].中华全科医师杂志，2019，18（3）：250-255.
[13]	何昱，石森林，张茹萍，等.雷公藤多苷主要有效成分的含量研究[J].药物分析杂志，2013，33（2）：197-200.
[14]	王丽平，陈雪芬，赵茂，等.单核巨噬细胞亚群在结缔组织病相关间质性肺病中的表达研究[J].天津医药，2019，12（11）：143-144.
[15]	孙明月，王志英.间质性肺疾病的中医临床研究进展[J].湖南中医杂志，2018，14（2）：156-157.
[16]	胡怀霞.雷公藤多甙治疗结缔组织病相关肺间质病变的初步临床观察[J].实用医学杂志，2015，14（19）：3247-3249.
[17]	林嘉鸿，黎志锋，罗绮雯，等.糖皮质激素联合雷公藤多苷治疗结缔组织病相关间质性肺疾病的临床观察[J].上海中医药大学学报，2017，31（2）：40-43.